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a b s t r a c t
Background: Intravenous amiodarone is considered to be the ﬁrst-line drug for the treatment of ventricular
tachycardia or ﬁbrillation. However, in Japan, nifekalant had been used before the introduction of
amiodarone; therefore, most clinical studies on amiodarone use have been small-scale studies. The aim of
the present study was to review the literature concerning the actual use of amiodarone and nifekalant in
order to evaluate the effects of both drugs and the most appropriate mode of administration.
Methods: The Japan Medical Abstracts Society, PubMed, and Scopus databases were used to identify the
reports. The resulting data were used for a systematic review focusing on the effectiveness of amiodarone in
comparison with that of nifekalant and the dose differential effect of amiodarone.
Results: The search returned 9 studies, including 310 patients, that compared the effectiveness of amiodarone
and nifekalant, as well as 3 studies, including 108 patients, that analyzed the effectiveness of treatment
according to amiodarone dose. Of 418 patients, 187 in whom amiodarone was used for cardiopulmonary
resuscitation (CPR) were included in a review that compared the doses recommended by Japanese guidelines
2009 (125mg intravenous [i.v.] over 10min) and the American Heart Association guidelines (300 mg bolus i.
v.). Amiodarone and nifekalant were equally effective in preventing electrical storm (67% vs. 67%). The
deﬁbrillation effect for CPR was also equal in the 2 groups (60% vs. 54%). Hypotension and bradycardia were
recorded as adverse effects in the amiodarone group (9.5% and 5.3%), whereas torsades de pointes was
observed in the nifekalant group (1.4%). In the analysis of the dose-differential effect of amiodarone, the rates of
successful return of spontaneous circulation and discharge survival were higher in the 125-mg slow i.v. group
than in the 300-mg bolus i.v. group (76% vs. 53% and 54% vs. 26%, respectively).
Conclusions: Amiodarone and nifekalant were equivalent in their prophylactic and deﬁbrillation efﬁcacy.
Concerning the initial amiodarone dose, the 125 mg intravenous [i.v.] over 10 min seemed to be more
appropriate for the Japanese population.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Intravenous amiodarone has been established as the ﬁrst-line
drug for cardiopulmonary resuscitation (CPR) in patients with fatal
ventricular arrhythmias [1]. However, in Japan, intravenous (i.v.)
nifekalant hydrochloride was in common use from 1999 until i.v.
amiodarone was approved in June 2007. Nifekalant interferes with
the delayed rectiﬁer Kþ channels, particularly the rapid compo-
nent of the IKr current, as well as the inward rectiﬁer IK1 current
and the transient outward Ito channel [2,3]. In contrast, amiodar-
one has multiple effects, including blockade of the beta-adrenergic
receptors, the fast inward Naþ current, the L-type Ca2þ current,
and the fast and slow components of the delayed rectiﬁer Kþ
current (IKr and IKs) [4]. According to the 2005 CPR guidelines of
the American Heart Association (AHA) [1], 300 mg of i.v. amiodar-
one should be used for the initial dose. The following recommen-
dations have been issued in Japan as a ﬁrst guideline [5]:
(1) 125 mg/10 min i.v. for the initial dose, (2) 50 mg/h drip i.v.
(d.i.v.) for 6 h, and (3) 25 mg/h d.i.v. for maintenance.
We have used nifekalant for CPR and for the ﬁrst time reported
the favorable deﬁbrillation effect of nifekalant in the treatment of
refractory ventricular tachycardia and ﬁbrillation (VT/VF) [6–8].
We also compared the usefulness of amiodarone with that of
nifekalant and reported that the deﬁbrillation efﬁcacy was
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equivalent between these drugs [9]. In contrast, Yoshioka et al. [10]
reported the dynamic variance of the ventricular late potentials
induced by the Naþ channel-blocking action of intravenous
amiodarone and suggested the possibility of a negative chrono-
tropic action of amiodarone when delivered i.v. for CPR.
Amiodarone has been used in Japan for more than 5 years now
since its approval in July 2007, and intravenous amiodarone has
been widely used for life-threatening ventricular tachycardia in
the setting of critical care medicine. However, only few reports
have been published in the international literature about the
effects of amiodarone in a Japanese population. The purpose of
this paper was to review the literature concerning the Kþ channel
blockers amiodarone and nifekalant and to discuss the effects of
both drugs and the most appropriate mode of administration.
2. Material and methods
2.1. Literature search
The Japan Medical Abstracts Society, PubMed, and Scopus
databases were used to identify abstracts, national proceedings,
and Japanese or English papers for systematic review, using the
following keywords: “nifekalant,” “amiodarone,” “VT/VF,” “cardio-
pulmonary arrest (CPA),” and “CPR.” Articles published between
July 2007 and December 2012 were retrieved. Case reports from
single centers were excluded. All the subjects were Japanese.
Two public reliable meta-analysis software, Review Manager
(Rev Man) [11] and GRADE proﬁler [12], were used in the
statistical analysis. A forest plot was constructed to investigate
any inconsistency of results. A funnel plot was used for evaluating
whether a publication bias exists. A general variance-based
method was used for the calculation of odds ratio (OR) and
conﬁdence interval (CI) in a meta-analysis. However, a simple
pooled analysis was used in the case of an inappropriate meta-
analysis. Signiﬁcant differences were computed using the chi-
square (nZ5) and Fisher exact tests (no5).
3. Results
3.1. Studies comparing outcomes between nifekalant and
amiodarone
 The search results included 9 articles [13–20] that compared
“the effects of amiodarone and nifekalant (deﬁned study 1)”
and 3 articles [21–23] comparing “the effects of different doses
of amiodarone (deﬁned study 2).”
 Eight articles [13–15,19,21–23] were from the conference
proceedings of the Amiodarone Workshop (Japanese). Two
articles [17,18] were original papers in Japanese, one [9] an
original paper in English and the other [20] a conference
abstract from the Journal of Arrhythmia.
 Eleven articles [13–23] were retrospective observational stu-
dies, and the other one [9] was a prospective study.
All these articles were published between 2010 and 2012. Study 1
included 310 patients (Table 1), of whom 196 were in-hospital cases
and 114 were out-of-hospital cases. The main issues focused on by the
studies were as follows:
 Prevention of recurrent ventricular arrhythmias, by Sasaki et al.
[13] (n¼42)
 Prophylactic effect on electrical storm (ES), by Sasaki et al. [13]
(n¼12), Maeda et al. [14] (n¼7), Miyauchi [15] (n¼21), and
Mera et al. [16] (n¼74).
 Deﬁbrillation effect on VT/VF for in-hospital CPA patients, by
Takahashi et al. [17] (n¼40).
 Deﬁbrillation effect on VT/VF for out-of-hospital CPA patients,
by Amino et al. [9] (n¼30), Ito et al. [18] (n¼39), Hayakawa
et al. [19] (n¼24), and Yamamoto et al. [20] (n¼21).
Generally, ES was deﬁned as a serious and intractable arrhyth-
mia attack in which VT/VF appears more than 2 or 3 times within
24 h, requiring direct current shock. Prevention was deﬁned as the
breakdown of ES and inhibition of VT/VF recurrences.
The rate of preventative effect against ventricular arrhythmias
was 74% for amiodarone and nifekalant by 1 institution report
(p¼0.74) [13]. The prophylactic effects of amiodarone and nifeka-
lant against ES were similar (p¼0.99) in 4 institution reports [13–
16]. The deﬁbrillation effect on VT/VF in the patients undergoing
in-hospital CPA had no signiﬁcance between the amiodarone and
nifekalant groups (73% vs. 48%, p¼0.29) by 1 institution report
[17]. The success rates of deﬁbrillation by amiodarone and nife-
kalant in the patients undergoing out-of-hospital CPA were similar
(p¼0.93) in 4 institution reports [9,18–20]. Meta-analysis was
applied to the studies on “the prophylactic effect of ES” and
“deﬁbrillation of VT/VF for out-of-hospital CPA.” The results
(Fig. 1) showed no signiﬁcance between amiodarone and nifeka-
lant in terms of prophylactic effect (OR, 1.02; 95% CI, 0.45–2.29;
Fig. 1A) and in the investigation of deﬁbrillation success (OR, 1.39;
95% CI, 0.60–3.06; Fig. 1B). These class III antiarrhythmic drugs
clearly demonstrated more than 50% efﬁcacy for treating any fatal
arrhythmia. However, publication bias was not evaluated by the
statistical analysis of the funnel plot because of the small number
of publications included.
The frequency rates of adverse effects in the patients in whom
deﬁbrillation with amiodarone was successful (n¼75) were as
follows: hypotension, 12.0%; bradycardia, 9.3%; and severe QT
prolongation (4600 ms), 5.3%. In the nifekalant group (n¼71),
no hypotension or bradycardia occurred, but severe QT prolonga-
tion was observed in 12.7% of the patients and torsades de pointes
was observed in 1.4%.
3.2. Patient population in study 1
Of the total 310 patients, 152 were designated as the amiodarone
group and 158 were designated as the nifekalant group. The
demographic and clinical data of the patients in study 1 are shown
in Table 2. The patient age was speciﬁed for 163 patients; the
mean7SD age was 64715.3 years (n¼86) in the amiodarone group
and 64716.8 years (n¼77) in the nifekalant group. Sex was
speciﬁed for 103 of the 310 patients; the ratio of the male subjects
was 75% (40/53) in the amiodarone group and 76% (38/50) in the
nifekalant group. The targeted fatal arrhythmia was 25VT, 25VF, and
3VT/VF in the amiodarone group (n¼53) and 23VT, 23VF, and 3VT/
VF in the nifekalant group (n¼49). The time interval from basic life
support to anti-arrhythmic drug administration was 54729.8 min
(n¼57) in the amiodarone group and 47717.9 min in the nifekalant
group (n¼36). For the 93 patients who underwent laboratory
examinations, the arterial blood pH on arrival was 7.0470.21
(n¼57) in the amiodarone group and 7.0470.19 (n¼36) in the
nifekalant group. For the 54 patients, the serum Kþ level on arrival
was 4.970.8 mEq/L (n¼32) in the amiodarone group and 4.670.9
(n¼22) in the nifekalant group. The underlying disease was speciﬁed
for 84 patients as follows. Of the 36 patients in the amiodarone
group, ischemic heart disease was observed in 16 (44%); cardiomyo-
pathy, in 12 (33%); and other conditions, in 8 (22%). Of the 48 patients
in the nifekalant group, ischemic heart disease was observed
in 20 (47%); cardiomyopathy, in 14 (33%); and other conditions, in
9 (19%). For the 72 patients who underwent an echocardiographic
examination, the ejection fraction (EF) was 42%72.8% in the
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amiodarone group (n¼34) and 36%72.8% in the nifekalant group
(n¼38).
3.3. Differential effect of amiodarone dose (study 2)
Three single-center reports were related to evaluations of
different doses of amiodarone (Table 3). These were retrospective
studies including 108 CPA patients. Kobori et al. [21] evaluated the
return of spontaneous circulation (ROSC) rate in patients with in-
hospital/out-of-hospital CPA, comparing the following 2 different
regimens: (i) 125 mg slow i.v. (n¼28) and (ii) 150–300 mg i.v.
(n¼26). “Slow i.v.” means a bolus injection over 10 min, according
to the guidelines of the Japanese Circulation Society [5]. The ROSC
rate was 93% in the former group and 46% in the latter. However, no
clear conclusions could be drawn because of the uneven distribu-
tion of the population backgrounds (age, underlying disease, cardiac
function, etc.). Matsuo et al. [22] investigated the hospitalization
rate and discharge survival rate in the patients with out-of-hospital
CPA in the following 2 groups: (i) 300 mg i.v. (n¼15) and (ii)
300 mgþadditional 150 mg i.v. (n¼19). The ROSC success rate was
Table 1
Comparison between the effectiveness of amiodarone and that of nifekalant.
No. Author Content of study n¼310
(Male)







1 Sasaki et al. [13] Prevention of the recurrent
ventricular arrhythmias






23 66 17 (74) 2 prolonged
excessive QT
1 TdP
Prophylactic effect of electrical
storm
12 (–) 3 – 1 (33)
0.99
9 – 6 (67)
2 Maeda et al. [14] Prophylactic effect of electrical
storm
7 (4) 2 62 1 (50)
5 69 3 (60)
3 Miyauchi et al. [15] Prophylactic effect of electrical
storm
21 (–) 8 65 5 (63)
13 65 8 (62)
4 Mera et al. [16] Prophylactic effect of electrical
storm
74 (–) 41 – 29 (71) 4 hypotension
4 bradycardia
33 – 23 (70) 3 prolonged
excessive QT
5 Takahashi et al. [17] Deﬁbrillation of VT/VF for in-
hospital CPA
40 (–) 11 – 8 (73)
0.2929 – 14 (48)
6 Amino et al. [9] Deﬁbrillation of VT/VF for out-of-
hospital CPA




15 62716.3 7 (47) 0
7 Ito et al. [18] Deﬁbrillation of VT/VF for out-of-
hospital CPA
21 (–) 11 – 6 (55)
10 – 5 (50)
8 Hayakawa et al. [19] Deﬁbrillation of VT/VF for out-of-
hospital CPA
24 (22) 17 61715.6 7 (41)
7 59719.0 2 (29)
9 Yamamoto et al. [20] Deﬁbrillation of VT/VF for out-of-
hospital CPA
39 (–) 25 65716 18 (72)
14 64715 11 (79)
VT/VF: ventricular tachycardia/ﬁbrillation, CPA: cardiopulmonary arrest, TdP: torsade de pointes.
Author
Sasaki et al. [13]
Maeda et al. [14]
Miyauchi [15]
Mera et al. [16]
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Fig. 1. Results of the meta-analysis. (A) Forest and funnel plots of the prophylactic effect of electrical storm. (B) Forest and funnel plots of successful deﬁbrillation effect for
out-of-hospital VT/VF. No signiﬁcant comparative merits were found between amiodarone and nifekalant. OR: odds ratio, CI: conﬁdence interval, NIF: nifekalant, AMD:
amiodarone.
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80% in the former group and 47% in the latter. However, according
to the authors, no signiﬁcant difference was found between the
groups (reason unknown). Kubo et al. [23] studied the ROSC and
discharge survival rates in the patients with out-of-hospital CPA,
comparing the following 3 groups: (i) 125 mg slow i.v. (n¼3), (ii)
300 mg i.v. (n¼9), and (iii) 300 mgþadditional 150 mg i.v. (n¼8).
The ROSC success rate was 100%, 56%, and 47%. However, no
signiﬁcant differences could be determined between the 3 groups,
possibly because of the small number of subjects in the ﬁrst group.
Although these 3 reports did not provide signiﬁcant statistical
ﬁndings regarding the effectiveness of different doses of i.v.
amiodarone, the results appear to suggest that slow injection with
a minimal dose might have an advantage in terms of CPR outcomes.
Regarding the adverse effects of amiodarone, Kobori et al. [21]
reported that the 125-mg slow i.v. group showed comparatively
less-severe events (1 case of bradycardia and 1 of hypotension),
whereas the 150- to 300-mg i.v. group exhibited severe events,
leading to pulseless electrical activity (PEA) and asystole in
8 patients. Even after successful ROSC was achieved, the combined
use of a catecholamine with amiodarone was needed in all 12
cases in the 150- to 300-mg i.v. group. These observations suggest
that with higher doses of amiodarone, it becomes more difﬁcult to
maintain hemodynamic stability.
3.4. Japanese and AHA guidelines for amiodarone in CPR
As stated earlier, of the 418 (310þ108) patients included in
study 2, 187 were treated with amiodarone (Table 4). The subjects
were all CPA cases. They were divided into 2 groups as follows:
(i) lower dose (125 mg) with slow i.v., according to the Japanese
guidelines 2009, and (ii) higher dose (almost 300 mg or more) as a
bolus, based on the AHA guidelines. The Japanese guideline group
consisted of 93 patients in 6 hospitals, and the AHA guideline
group consisted of 94 patients in 4 hospitals. The ROSC success
rate was 76% (71/93) in the former group and 53% (50/94) in the
latter group. The discharge survival rate was reported for 82 of the
93 patients in the Japanese guideline group and for all 94 patients
in the AHA guideline group. The rates were 54% (44/82) in the
former group and 26% (24/94) in the latter group. Thus, a smaller
dose with slow administration appeared to be better in terms of
ROSC outcome and discharge survival. However, statistical analysis
was not performed in this study.
4. Discussion
In study 1, which compared the effectiveness of amiodarone
and nifekalant in 310 patients, both agents appeared to be almost
equal in terms of prophylactic effect against ES and deﬁbrillation
effect in CPR. Hypotension and bradycardia were observed as
adverse effects in the amiodarone group, and torsades de pointes
was the adverse effect observed in the nifekalant group. In study 2,
which compared the effectiveness of amiodarone doses in 187
patients, the ROSC success and discharge survival rates were
higher in the 125-mg slow i.v. group than in the 300-mg bolus
group. One report [21] suggested that PEA and asystole were more
likely to occur in the high-dose amiodarone group.
4.1. Comparison between the effectiveness of amiodarone and that of
nifekalant
This systematic review revealed that amiodarone and nifeka-
lant were excellent for the prophylaxis of ventricular tachyar-
rhythmia and deﬁbrillation during CPR. However, the discharge
Table 2
Patient populations in the studies comparing outcomes between nifekalant and amiodarone.
Speciﬁed number of patients (n/310) Amiodarone Nifekalant
Age, years 163 64715.3 64716.8
Sex (male) 103 40 (75%) 38 (76%)
Targeted fatal arrhythmia 102 VT 25 (47%) 23 (46%)
VF 25 (47%) 23 (46%)
VT/VF 3 (6%) 3 (6%)
Time interval from basic life support to anti-arrhythmic drug administration 93 54729.8 min 47717.9 min
Atrial blood pH on arrival 93 7.0470.21 7.0470.19
Serum Kþ level (mEq/L) on arrival 54 4.970.8 4.670.9
Underlying disease 84 Ischemic heart disease 16 (44%) 20 (47%)
Cardiomyopathy 12 (33%) 14 (33%)
Others 8 (22%) 9 (19%)
EF (%) examined by echocardiography 72 4272.8% 3672.9%
EF: ejection fraction, VT/VF: ventricular tachycardia/ﬁbrillation.
Table 3
Dose differential effect of amiodarone.







1 Kobori et al. [21] Deﬁbrillation effect of VT/VF by
amiodarone
for in-hospital CPA/out-of-hospital CPA




12/26 (46%) 8 PEA/
asystole
2 Matsuo et al.
[22]
Deﬁbrillation effect of VT/VF by
amiodarone
for out-of-hospital CPA
34 (26) 58 300 mg i.v. 12/15 (80%)
300 mg i.v.þadditional 150 mg i.
v.
9/19 (47%)
3 Kubo et al. [23] Deﬁbrillation effect of VT/VF by
amiodarone
for out-of-hospital CPA
20 (32) 41 125 mg slow i.v. 3/3 (100%)
300 mg i.v. 5/9 (56%)
300 mg i.v.þadditional 150 mg i.
v.
5/8 (63%)
VT/VF: ventricular tachycardia/ﬁbrillation, CPA: cardiopulmonary arrest, ROSC: return of spontaneous circulation, PEA: pulseless electrical activity.
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survival rate could not be examined because of the lack of
information regarding the prognosis in the 310 patients. In our
single-center comparative study between amiodarone and nifeka-
lant [9], the discharge survival rate did not differ signiﬁcantly
between the 2 groups (53% vs. 21%, p¼0.06). Notably, all 4 survi-
vors in the nifekalant group were able to resume normal daily life
after hospital discharge, whereas this was possible for only 2 of the
11 survivors in the amiodarone group. The difference was probably
partly attributable to the longer time between drug administration
and deﬁbrillation success in the amiodarone patients than in the
receiving nifekalant. Although amiodarone is now the ﬁrst-line
drug used for CPR, nifekalant could be viewed as a useful
alternative.
Apart from some case reports, we found no data concerning the
combined use of amiodarone and nifekalant. We previously
reported that the consecutive use of nifekalant after lidocaine
sometimes induced an unexpected effect in CPA patient; that is,
the combination of the 2 drugs often provoked sudden asystole
[6,7]. Regarding the mechanism of this serious adverse effect, we
hypothesized that progression of metabolic acidosis is associated
with CPA leading to reduced effects of intrinsic catecholamine and
retard the pharmacological dissociation of Naþ channel blocker.
The absence of any atrial or ventricular escape rhythm suggest that
severe hypoperfusion and drug administration might cause a
diffuse suppressive effect on conduction involving the sinus node,
atrioventricular node, and Purkinje ﬁbers. Interaction between
lidocaine and nifekalant increased the suppressive effect on IKr, IKs,
and INa within the sinus node. Similar considerations apply to the
multichannel blocker, amiodarone. The effects of intravenous
amiodarone on cardiac Naþ channels are similar to lignocaine
(lidocaine) in terms of their blocking and unblocking kinetics [24].
Lidocaine-like Naþ channel blocking action may play a dual role in
the development of antiarrhythmia or proarrhythmia. If amiodar-
one and nifekalant are to be used at the same time, each half dose
should be given cautiously.
4.2. Effectiveness according to amiodarone dose
In 2007, Katoh et al. [25] ﬁrst reported the effectiveness of
intravenous amiodarone in Japanese patients based on open-label,
uncontrolled, multicenter studies conducted in 39 medical facil-
ities. Amiodarone was administered as an initial infusion of
125 mg over 10 min. The dose levels were based on data from a
dose-determination study conducted in the United States, after
taking into account the difference in body weight between
Americans and Japanese [26–28]. The efﬁcacy and safety of the
drug in preventing acute relapse of VT/VF were well demonstrated
for this dose and delivery method. No severe effects related to
amiodarone were observed to be associated with the method of
initial infusion of 125 mg over 10 min.
The best-known large clinical studies are the ARREST [29]
(amiodarone for resuscitation after out-of-hospital cardiac arrest
due to ventricular ﬁbrillation) and ALIVE [30] (amiodarone as
compared with lidocaine for shock-resistant ventricular ﬁbrilla-
tion) trials. ARREST, whose ﬁndings were published in 1999, was
the ﬁrst study to conﬁrm the effect of amiodarone for out-of-
hospital CPA patients. Amiodarone or placebo was administered
for deﬁbrillator-resistant VT/VF. Among 504 subjects, primary
survival from VT/VF was 44% (108/246) in the amiodarone group,
compared with the 34% (89/258) in the placebo group (p¼0.03).
Three years later, ALIVE, in which lidocaine was used as a control
for amiodarone, demonstrated that the hospitalization survival
rate was 22.8% (41/180) in the amiodarone group, compared with
the 12.0% (20/167) in the lidocaine group (p¼0.009). However,
despite the increased ROSC success and hospitalization survival
rates, amiodarone could not improve the discharge survival rate
compared with the placebo and lidocaine groups.
In this systematic review, not only the ROSC success rate but
also the discharge survival rate was superior in the Japanese
guideline group compared with the AHA guideline group. These
ﬁndings provide new insight into the traditional AHA CPR
guidelines.
4.3. Appropriate administration method of amiodarone
Some questions remain to be answered. In practice, the method
of slow injection over 10 min is too slow for an emergency
situation. How can we use amiodarone and achieve prompt
results? Early deﬁbrillation can be achieved by giving a rapid
bolus injection with a high dose of amiodarone, and good recovery
of brain function may also be expected. Meanwhile, PEA/asystole
or severe bradycardia may be induced by such amiodarone
administration procedures. Because amiodarone acts on multiple
ion channels and thus decreases the excitability of ventricular
myocardium and sinus node cells, such procedures could promote
vascular dilatation and a negative inotropic effect, subsequently
resulting in hypotension and shock. In such cases, the combined
use of a catecholamine with amiodarone cannot be avoided. We
would need to know the potential increase in the risk of VF
Table 4
Comparison between the doses recommended by the Japanese and AHA guidelines.
Subject Method of amiodarone administration n¼187 ROSC success, n (%) Survival discharge, n (%)
Japanese CPR guidelines
Takahashi et al. [17] IHCPA 125 mg slow i.v. 11 8 (73) –
Amino et al. [9] OHCPA 125 mg slow i.v. 15 10 (67) 8 (53)
Ito et al. [18] OHCPA 125 mg slow i.v. 11 6 (55) 4 (36)
Yamamoto et al. [20] OHCPA 125 mg slow i.v. 25 18 (72) 11 (44)
Kobori et al. [21] IHCPA/OHCPA 125 mg slow i.v. 28 26 (93) 20 (71)
Kubo et al. [23] OHCPA 125 mg slow i.v. 3 3 (100) 1 (33)
Total 93 71 (76) 44/82 (54)
AHA CPR guidelines
Hayakawa et al. [19] OHCPA (150)–300 mg i.v. (average 237 mg) 17 7 (41) 5 (29)
Kobori et al. [21] IHCPA/OHCPA (150)–300 mg i.v. (average 283 mg) 26 12 (46) 8 (31)
Matsuo et al. [22] OHCPA 300 mg i.v. 15 12 (80) 6 (40)
300 mg i.v.þ150 mg additional i.v. 19 9 (47) 2 (11)
Kubo et al. [23] OHCPA 300 mg i.v. 9 5 (56) 1 (11)
300 mg i.v.þ150 mg additional i.v. 8 5 (63) 2 (25)
Total 94 50 (53) 24 (26)
CPA: cardiopulmonary arrest, IHCPA: in-hospital CPA, OHCPA: out-of-hospital CPA, ROSC: return of spontaneous circulation, PEA: pulseless electrical activity.
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occurrence by catecholamine, for if VF were to be initiated again,
there would be little hope of rescuing the patient.
The 8 reports summarized in this article provide insight as to
the appropriate administration rate and amiodarone dose for CPR.
However, a limitation of the present study was that the statistical
analysis did not take into account multiple disease-related factors
such as age, underlying disease, severity, bystander CPR, cardiac
arrest interval, and adverse effects. It cannot be denied that the
results might have been different if the data were subjected to a
multivariate analysis. A larger number of cases is necessary to
resolve this problem. For this purpose, a large-scale survey on CPR,
the SOS-KANTO Study 2012, has already been in progress by the
KANTO Region of Japanese Association for Acute Medicine (http://
www.jaam-kanto.jp/about_sos_kanto.html). More than 15,000
CPA cases have already been banked in the center during the last
year. The analyses of all these data warrant the establishment of
important guidelines for the actual uses of amiodarone.
4.4. Limitations
For increasing the Japanese population in this study, not only
original papers but also conference proceedings and abstracts
were included. Thus, the quality of each article is a major problem,
and careful interpretation is necessary for the meta-analysis, with
a high statistical conﬁdence level. Because the studies were not
randomized trials and only few examinations were performed, a
systematic review was adopted instead of a meta-analysis. The
results of study 1 remain only for reference. From these ﬁndings,
we could not conclude the superiority of amiodarone to nifekalant.
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